Videira M A, Santos A C, Botelho M F
Research Institute for Medicines and Pharmaceutical Sciences (iMed.UL), Faculty of Pharmacy, University of Lisbon. Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal.
Curr Radiopharm. 2012 Apr;5(2):158-65. doi: 10.2174/1874471011205020158.
The advent of nanomedicine and increase knowledge on cellular and molecular biology has opened new opportunities on the clinical field. Selective drug targeting and protection of healthy tissues rules the rising interest that is being devoted to drug delivery system strategies, considering that the accurate choice of the carrier molecule will determine the pharmacokinetics and pharmacodynamics of drugs, yielding higher therapeutic efficacy. Despite the improvements in surgery and immunological approaches, tumor staging and cancer therapy remains a challenge, typically because they are ineffective in advanced stages of the disease, but also due to the conventional administration route (intravenous), and consequently the non-specificity of the potentially toxic drugs. The issue currently under the spotlight in drug targeting is the concept of drug delivery systems (DDS) and the impact that is inherent to their selectivity. Moreover, these particulate systems bring forth the possibility of using alternative routes to the conventional intravenous administration. This article reviews the applications of gamma-scintigraphic image technique to evaluate the advances and research on DDS engineering to the pulmonary administration, and the dependency of lung particle removal mechanism on both the administration route and the particulate system characteristic, based on literature data, as well as through the experimental studies performed in our group.
纳米医学的出现以及对细胞和分子生物学认识的增加为临床领域带来了新机遇。鉴于载体分子的准确选择将决定药物的药代动力学和药效学,从而产生更高的治疗效果,选择性药物靶向和健康组织保护成为人们对药物递送系统策略日益关注的焦点。尽管手术和免疫方法有所改进,但肿瘤分期和癌症治疗仍然是一项挑战,这通常是因为它们在疾病晚期无效,还由于传统给药途径(静脉内),以及潜在有毒药物的非特异性。目前药物靶向领域的热点问题是药物递送系统(DDS)的概念及其固有的选择性影响。此外,这些微粒系统带来了使用替代传统静脉内给药途径的可能性。本文基于文献数据以及我们小组进行的实验研究,综述了γ闪烁成像技术在评估肺部给药的DDS工程进展和研究中的应用,以及肺部颗粒清除机制对给药途径和微粒系统特性的依赖性。